X0306 4 2018-09-28 0 0001626199 ALPINE IMMUNE SCIENCES, INC. ALPN 0001711352 PENG STANFORD L C/O ALPINE IMMUNE SCIENCES, INC. 201 ELLIOTT AVENUE WEST, SUITE 230 SEATTLE WA 98119 0 1 0 0 See Remarks Stock Option (Right to buy) 6.33 2018-09-28 4 A 0 250000 0.00 A 2028-09-27 Common Stock 250000 250000 D The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant. 1/2 of the shares subject to the option become vested and exercisable on October 1, 2020 and the balance of the shares subject to the option become vested and exercisable on October 1, 2022, subject to continued service through each such date. Exec VP of Research and Development and CMO /s/ James Paul Rickey, attorney-in-fact 2018-10-01